問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans Center Hospital Yuli Branch (在職)

Division of Hematology & Oncology

Division of Psychiatry

China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Yuli Hospital Ministry of Health and Welfare (在職)

Division of Hematology & Oncology

Division of Psychiatry

National Taiwan University Hospital Yunlin Branch  (在職)

Division of Psychiatry

國立臺灣大學醫學院附設醫院雲林分院

更新時間：2023-09-19

陳姿婷Chen, Tzu-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

90Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳姿婷

List

156Cases

2022-05-02 - 2027-03-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2022-09-01 - 2028-12-31

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
4Sites

Recruiting4Sites

2022-04-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-09-01 - 2025-04-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2023-06-12 - 2027-05-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

2022-09-01 - 2029-12-31

Phase III

Active
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 1 Prior Line of Therapy

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Talquetamab;Daratumumab;Pomalidomide;Dexamethasone

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2021-10-15 - 2026-12-23

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2021-07-14 - 2026-11-30

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-02-19 - 2025-12-31

Phase I

Completed
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL

  • Condition/Disease

    Non-Hodgkin Lymphoma/Chronic lymphoid leukemia

  • Test Drug

    JNJ-75348780

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2022-10-01 - 2024-09-26

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB